Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study

Gynecologic Oncology

Volumn 115, Issue 3, 2009, Pages 382-388

  Joly, F ^a,b   Petit, T ^c   Pautier, P ^d   Guardiola, E ^e   Mayer, F ^f   Chevalier Place, A ^g   Delva, R ^h   Sevin, E ^a   Henry Amar, M ^a   Bourgeois, H ⁱ  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c CENTRE PAUL STRAUSS   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^f CENTRE GEORGES FRANÇOIS LECLERC   (France)

^g CENTRE OSCAR LAMBRET   (France)

^h CENTRE PAUL PAPIN   (France)

ⁱ CENTRE JEAN BERNARD   (France)

Author keywords

Clinical benefit; Gemcitabine; Ovarian carcinoma; Quality of life; Topotecan

Indexed keywords

GEMCITABINE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OVARIAN NEOPLASMS; QUALITY OF LIFE; TOPOTECAN; TREATMENT OUTCOME;

EID: 70350566077     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.08.024     Document Type: Article

References (45)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 57 (2007) 43-66
2. Visintin I., Feng Z., Longton G., Ward D.C., Alvero A.B., Lai Y., et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14 (2008) 1065-1072
3. Neijt J.P., ten Bokkel Huinink W.W., van der Burg M.E., van Oosterom A.T., Willemse P.H., Vermorken J.B., et al. Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur. J. Cancer 27 (1991) 1367-1372
4. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III-IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
5. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92 (2000) 699-708
6. Bookman M.A., Greer B.E., and Ozols R.F. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int. J. Gynecol. Cancer 13 (2003) 735-740
7. du Bois A., Lück H.J., Meier W., Adams H.P., Möbus V., Costa S., et al. Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003) 1320-1329
8. Ozols R.F., Bundy B.N., and Greer B.E. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
9. Cancer Research UK, Cancer Stats Ovarian Cancer-UK (2004) http://info.cancerresearchuk.org/.
10. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl 5 (2002) 20-28
11. Kavanagh J., Tresukosol D., Edwards C., Freedman R., Gonzalez de Leon C., Fishman A., et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol. 13 (1995) 1584-1588
12. Fields A.L., and Runowicz C.D. Current therapies in ovarian cancer. Cancer Invest. 21 (2003) 148-156
13. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 (2001) 3312-3322
14. Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D., et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 25 (2007) 2811-2818
15. Dabrow M.B., Francesco M.R., Gilman P.B., Cantor R., Rose L., and Meyer T.J. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer. Cancer Invest. 21 (2003) 517-525
16. Gore M., ten Bokkel Huinink W., Carmichael J., Gordon A., Davidson N., Coleman R., et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J. Clin. Oncol. 19 (2001) 1893-1900
17. Herzog T.J. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist 7 Suppl 5 (2002) 3-10
18. Ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15 (1997) 2183-2193
19. Safra T., Menczer J., Bernstein R., Shpigel S., Inbar M.J., Grisaru D., et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol. Oncol. 105 (2007) 205-210
20. Largillier R., Valenza B., Ferrero J.M., Novo C., Creisson A., Lesbats G., et al. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. Oncology 73 (2007) 177-184
21. Goff B.A., Holmberg L.A., Veljovich D., and Kurland B.F. Puget Sound Oncology Consortium. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium. Gynecol. Oncol. 110 (2008) 146-151
22. Morris R., Alvarez R.D., Andrews S., Malone J., Bryant C., Heilbrun L.K., et al. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol. Oncol. 109 (2008) 346-352
23. Lund B., Hansen O.P., Theilade K., Hansen M., and Neijt J.P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J. Natl. Cancer Inst. 86 (1994) 1530-1533
24. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Review. Semin. Oncol. 29 1 Suppl 1 (2002) 9-10
25. Choy H., Kim J.S., Pyo H., and MacRae R. Topoisomerase I inhibitors in the combined modality therapy of lung cancer. Clin. Lung Cancer 2 Suppl 2 (2001) S34-S40
26. Rinaldi D.A., Lormand N.A., Brierre J.E., Cole J.L., Barnes B.C., Mills G., et al. A phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma. Cancer 95 (2002) 1274-1278
27. Joppert M.G., Garfield D.H., Gregurich M.A., Nemunaitis J.J., Marsland T.A., Khandelwal P., et al. A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer. Lung Cancer 39 (2003) 215-219
28. Sun W., Stevenson J.P., Gallagher M., Giantonio B., Algazy K., Haller D., et al. A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer 92 (2001) 414-419
29. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92 (2000) 205-216
30. Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J. Clin. Oncol. 14 (1996) 1545-1551
31. Basen-Engquist K., Bodurka-Bevers D., Fitzgerald M.A., Webster K., Cella D., Hu S., et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J. Clin. Oncol. 19 (2001) 1809-1817
32. Yellen S.B., Cella D.F., Webster K., Blendowski C., and Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J. Pain Symptom Manage 13 (1997) 63-74
33. Rothman K.J., and Boice Jr. J.D. Epidemiologic analysis with a programmable calculator (1982), Epidemiology Resources Inc., Boston
34. Stata statistical software, release 10.0. College Station, TX: Stata; 2007.
35. Morris R.T., Alvarez R.D., Malone J., Bryant C., Andrews S.J., Kilgore L., et al. Phase II study of weekly topotecan in patients with relapsed platinum-sensitive ovarian or peritoneal cancer. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 23 16S (2005) 5058
36. Rodriguez M., Method M.W., Lewandowski G., Vaccarello L., and Ansari R.H. A preliminary report of a phase II study of weekly topotecan in platinum-sensitive recurrent ovarian and peritoneal carcinoma. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 23 14S (2004) 5063
37. Bhoola S.M., Estes J.M., Leath III C.A., Kirby T.O., Bunch P., Barnes III M.N., et al. Weekly topotecan is well tolerated in the third-line or later treatment of patients with epithelial ovarian carcinoma (EOC) and may prolong time to disease progression. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 22 14S (2004) 5067
38. Trédaniel J., Blay J.Y., Goldwasser F., Asselain B., Koscielny S., de Labareyre C., et al. Decision making process in oncology practice: is the information available and what should it consist of?. Crit. Rev. Oncol. Hematol. 54 (2005) 165-170
39. Fung-Kee-Fung M., Oliver T., Elit L., Oza A., Hirte H.W., and Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr. Oncol. 14 (2007) 195-208
40. Blay J.Y., Koscielny S., Trédaniel J., Asselain B., Goldwasser F., Misset J.L., et al. Rationale and delineation of a composite Index of Relative Antitumoural Efficacy (In-RATE). Crit. Rev. Oncol. Hematol. 64 (2007) 106-114
41. Bodurka-Bevers D., Basen-Engquist K., Carmack C., Fitzgerald M.A., Wolf J.K., de Moor C., et al. Depression, anxiety and quality of life in patients with epithelial ovarian cancer. Gynecol. Oncol. 78 (2000) 302-308
42. Le T., Leis A., Pahwa P., Wright K., Ali K., Reeder B., et al. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment. Gynecol. Oncol. 92 (2004) 839-844
43. Guastalla J.P., and Dieras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br. J. Cancer 89 Suppl 3 (2003) S16-S22
44. Lakusta C.M., Atkinson M.J., Robinson J.W., Nation J., Taenzer P.A., and Campo M.G. Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol. Oncol. 81 (2001) 490-495
45. Herzog T.J. Recurrent ovarian cancer: how important is it to treat to disease progression?. Clin. Cancer Res. 10 (2004) 7439-7449